News – Page 875 – Endpoints News

Roche's triplet involving Tecentriq clears the PFS bar for melanoma when added to BRAF/MEK combo

6 years ago

Sarepta was stunned by the rejection of Vyondys 53. Now it's stunning everyone with a surprise accelerated approval

6 years ago

Stephen Hahn confirmed as new FDA chief

6 years ago

Bristol-Myers' strategy, BD chief Paul Biondi exited the company — just ahead of the $74B Celgene deal close

6 years ago

House passes Pelosi drug pricing bill on party-line vote

6 years ago

Kite Pharma's ex-CEO contradicts founder as CAR-T patent trial heats up, with conflicting valuations

6 years ago

Evenity finally wins EU approval; US-China biologics CDMO raises $60M

6 years ago

KRAS analysis vaults Merck's flagship Keytruda back into the spotlight

6 years ago

AstraZeneca joins Merck, Bristol-Myers in China's checkpoint race as regulators OK first PD-L1

6 years ago

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to ...

6 years ago

Correvio is putting itself up on the auction block after FDA review panel points to another rejection

6 years ago

In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle

6 years ago

Alphamab Oncology rounds out HKEX's second biotech IPO year with $230M raise and high local interest

6 years ago

For sale: Long-acting PhIII GLP-1 diabetes drug that’s way behind rivals, now spurned by Sanofi

6 years ago

Parkinson's transplants emerge as stem cell pioneer Jeanne Loring joins R&D race

6 years ago

FDA slaps down Alkermes for misleading Vivitrol ads — don't forget vulnerability to opioid overdose

6 years ago

FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug

6 years ago

Seattle Genetics details positive OS and PFS data for tucatinib in breast cancer

6 years ago

Stefan Fraenkel takes over as chief of Inceptua Group; Christi Shaw has a plan to make Yescarta safer

6 years ago

Battered, cash hungry Intec feels the burn of Novartis rejection

6 years ago

What does $6.9B buy these days in oncology R&D? AstraZeneca has a landmark answer

6 years ago

Bristol-Myers shows off a low-profile AML contender it gained from Celgene buyout — and they’re taking it ...

6 years ago

Deserted by Astellas and Merck, little Correvio still can't win over FDA panel concerned with its AFib drug's safety

6 years ago

New trade deal knocks out long-sought biologics protections for drugmakers

6 years ago

First page Previous page 872 873 874875876 877 878 Next page Last page